Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.